Spots Global Cancer Trial Database for thiotepa
Every month we try and update this database with for thiotepa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Freiburg ZNS-NHL Study | NCT00647049 | Primary Non Hod... | methotrexate Rituximab Cytarabine Thiotepa Carmustin | 18 Years - 65 Years | University Hospital Freiburg | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer | NCT00003068 | Breast Cancer Drug/Agent Toxi... | amifostine trih... cyclophosphamid... mitoxantrone hy... thiotepa peripheral bloo... | 16 Years - 70 Years | National Cancer Institute (NCI) | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | NCT01598025 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly... | total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom... | - 19 Years | Memorial Sloan Kettering Cancer Center | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors | NCT01342237 | Brain Tumors | HDCT 1(TTC), HD... | - | Seoul National University Hospital | |
| Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | NCT00002680 | Breast Cancer | filgrastim cyclophosphamid... megestrol aceta... melphalan tamoxifen citra... thiotepa conventional su... peripheral bloo... radiation thera... | 18 Years - | Yale University | |
| Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas | NCT02049580 | Lymphoma | Thiotepa Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Istituto Clinico Humanitas | |
| Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor | NCT02784054 | Intracranial No... | Carboplatin Etoposide Cyclophosphamid... Bleomycin Thiotepa Melphalan Reduced dose ra... | 3 Years - 30 Years | Samsung Medical Center | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | NCT00567567 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor | NCT02784054 | Intracranial No... | Carboplatin Etoposide Cyclophosphamid... Bleomycin Thiotepa Melphalan Reduced dose ra... | 3 Years - 30 Years | Samsung Medical Center | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma | NCT00008008 | Brain and Centr... | filgrastim sargramostim cyclophosphamid... thiotepa autologous bone... bone marrow abl... peripheral bloo... | - | National Cancer Institute (NCI) | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | NCT06013423 | Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid... | Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ... | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma | NCT00003101 | Brain and Centr... | filgrastim busulfan lomustine procarbazine hy... thiotepa vincristine sul... autologous bone... peripheral bloo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | NCT01807611 | Leukemia Lymphoma | Total Lymphoid ... Fludarabine Cyclophosphamid... Thiotepa Melphalan HPC,A Infusion TC-NK Infusion G-CSF Mesna CliniMACS Mycophenolate m... | - 21 Years | St. Jude Children's Research Hospital | |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | NCT03399773 | Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic... | Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr... | 10 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer | NCT00025558 | Brain and Centr... | filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo... | 1 Year - 49 Years | NYU Langone Health | |
| Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00101140 | Adult Acute Ery... Adult Acute Mon... Adult Acute Mye... | anti-thymocyte ... fludarabine pho... thiotepa biological ther... bone marrow abl... chemotherapy non-specific im... peripheral bloo... radiation thera... | 18 Years - 59 Years | Eastern Cooperative Oncology Group | |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | NCT04083170 | Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem... | Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | NCT00003080 | Ovarian Cancer | endocrine-modul... melphalan mitoxantrone hy... tamoxifen citra... thiotepa peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia | NCT00002704 | Leukemia | filgrastim asparaginase cyclophosphamid... daunorubicin hy... dexamethasone etoposide leucovorin calc... liposomal cytar... mercaptopurine mesna methotrexate therapeutic hyd... thiotepa vincristine sul... low-LET electro... low-LET photon ... | - 20 Years | National Cancer Institute (NCI) | |
| Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine | NCT06060782 | Burkitt Lymphom... Lymphoblastic L... Acute Lymphobla... | Thiotepa, cyclo... | 18 Years - 65 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | NCT05021770 | Refractory and ... PCNSL Non Hodgkin Lym... | Orelabrutinib Orelabrutinib Thiotepa | 18 Years - | Sun Yat-sen University | |
| Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia | NCT00002704 | Leukemia | filgrastim asparaginase cyclophosphamid... daunorubicin hy... dexamethasone etoposide leucovorin calc... liposomal cytar... mercaptopurine mesna methotrexate therapeutic hyd... thiotepa vincristine sul... low-LET electro... low-LET photon ... | - 20 Years | National Cancer Institute (NCI) | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | NCT00003173 | Brain and Centr... Childhood Germ ... Extragonadal Ge... Ovarian Cancer Retinoblastoma Testicular Germ... Unspecified Adu... Unspecified Chi... | filgrastim thiotepa autologous bone... peripheral bloo... | - | Memorial Sloan Kettering Cancer Center | |
| Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas | NCT02049580 | Lymphoma | Thiotepa Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Istituto Clinico Humanitas | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | NCT02329080 | Diffuse Large B... | Methotrexate Rituximab Cytarabine Thiotepa liposomial cyta... Etoposide Ifosfamide Carmustine whole brain rad... | 18 Years - 70 Years | International Extranodal Lymphoma Study Group (IELSG) | |
| Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | NCT00002471 | Leukemia Lymphoma | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... methotrexate methylprednisol... therapeutic hyd... thiotepa vincristine sul... | - | Memorial Sloan Kettering Cancer Center | |
| Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors | NCT00313521 | Brain and Centr... | thiotepa adjuvant therap... radiation thera... | 3 Years - 20 Years | National Cancer Institute (NCI) | |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | NCT03786783 | Ganglioneurobla... High Risk Neuro... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Dexrazoxane Dinutuximab Doxorubicin Etoposide External Beam R... Isotretinoin Melphalan Sargramostim Thiotepa Topotecan Vincristine | - 30 Years | National Cancer Institute (NCI) | |
| Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma | NCT00045539 | Lymphoma | leucovorin calc... methotrexate thiotepa | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | NCT00003297 | Ovarian Cancer | mitoxantrone hy... thiotepa topotecan hydro... peripheral bloo... | 18 Years - | Georgetown University | |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | NCT01119066 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Multiple Myelom... | total body irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine Clofarabine (CliniMACS) T-c... | - 69 Years | Memorial Sloan Kettering Cancer Center | |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | NCT04083170 | Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem... | Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | NCT03885947 | Hematological M... Acute Leukemia ... Acute Lymphobla... Myelodysplastic... Non-Hodgkin Lym... Hodgkin Lymphom... | Cord blood stem... Valproic Acid Fludarabine cytoxan Thiotepa TBI | 18 Years - 65 Years | Icahn School of Medicine at Mount Sinai | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | NCT01858740 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil... | Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra... | - 21 Years | Fred Hutchinson Cancer Center | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | NCT00003680 | Breast Cancer | CMF regimen cyclophosphamid... fluorouracil methotrexate tamoxifen citra... thiotepa peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer | NCT00025558 | Brain and Centr... | filgrastim carboplatin temozolomide thiotepa autologous bone... peripheral bloo... | 1 Year - 49 Years | NYU Langone Health | |
| High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas | NCT00078988 | Brain Tumor Central Nervous... | filgrastim carboplatin etoposide isotretinoin thiotepa autologous bone... peripheral bloo... | - 20 Years | Children's Oncology Group | |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | NCT04708054 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | Busulfan Cladribine Fludarabine Pho... Hematopoietic C... Thiotepa Venetoclax | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| CD34+ Transplants for Leukemia and Lymphoma | NCT05565105 | Leukemia, Myelo... Leukemia, Lymph... | Total Body Irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine | 18 Years - 74 Years | Baptist Health South Florida | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | NCT00004906 | Breast Cancer | filgrastim anastrozole carboplatin cisplatin cyclophosphamid... docetaxel doxorubicin hyd... etoposide pamidronate dis... thiotepa peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | NCT00004906 | Breast Cancer | filgrastim anastrozole carboplatin cisplatin cyclophosphamid... docetaxel doxorubicin hyd... etoposide pamidronate dis... thiotepa peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | NCT00002772 | Breast Cancer | filgrastim carboplatin carmustine cisplatin cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... thiotepa autologous bone... peripheral bloo... radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | NCT00004172 | Breast Cancer | filgrastim carboplatin cyclophosphamid... ifosfamide thiotepa peripheral bloo... radiation thera... | - 65 Years | Northwestern University | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors | NCT00025077 | Brain and Centr... | filgrastim carboplatin cyclophosphamid... thiotepa conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | NCT00005798 | Breast Cancer | Carboplatin Cyclophosphamid... Thiotepa | 15 Years - 64 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | NCT00002680 | Breast Cancer | filgrastim cyclophosphamid... megestrol aceta... melphalan tamoxifen citra... thiotepa conventional su... peripheral bloo... radiation thera... | 18 Years - | Yale University | |
| Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | NCT02784015 | Unresectable Lo... | Cisplatin Etoposide Doxorubicin Cyclophosphamid... Ifosfamide Carboplatin Radiotherapy Thiotepa Melphalan | - 18 Years | Samsung Medical Center | |
| Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | NCT00002977 | Ovarian Cancer | filgrastim melphalan thiotepa peripheral bloo... | 18 Years - 60 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | NCT00004092 | Breast Cancer | filgrastim carboplatin cyclophosphamid... doxorubicin hyd... paclitaxel thiotepa peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | NCT00038857 | Leukemia Lymphoma | Megadose of CD3... Melphalan Thiotepa Fludarabine Rabbit ATG | - 55 Years | M.D. Anderson Cancer Center | |
| Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | NCT00432094 | Childhood Germ ... Ovarian Cancer Teratoma | carboplatin etoposide ifosfamide paclitaxel thiotepa autologous hema... Mesna filgrastim | 10 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma | NCT02025881 | High-risk Medul... | Carboplatin + e... Thiotepa Cyclophosphamid... Temozolimide + ... Etoposide + rad... Temozolomide | - 5 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma | NCT02025881 | High-risk Medul... | Carboplatin + e... Thiotepa Cyclophosphamid... Temozolimide + ... Etoposide + rad... Temozolomide | - 5 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | NCT00001498 | Breast Cancer Breast Neoplasm... | methotrexate leucovorin 5-fluorouracil cyclophosphamid... peripheral bloo... paclitaxel doxorubicin | - | National Institutes of Health Clinical Center (CC) | |
| Infusion of Expanded Cord Blood T Cells | NCT00972101 | Stem Cell Trans... Leukemia Lymphoma Pediatric Disor... | Total Body Irra... Melphalan Thiotepa Fludarabine Rituximab Etoposide Anti-thymocyte ... Mycophenolate M... Tacrolimus Cord Blood Infu... G-CSF Ex vivo expande... | - 55 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma | NCT00017368 | Neuroblastoma | filgrastim sargramostim carboplatin cisplatin cyclophosphamid... doxorubicin hyd... etoposide etoposide phosp... ifosfamide isotretinoin melphalan thiotepa vincristine sul... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | NCT00317408 | Lymphoma | anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra... | - 21 Years | National Cancer Institute (NCI) | |
| Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System | NCT00867178 | Medulloblastoma Pineoblastoma Supratentorial ... | 3-Dimensional C... Carboplatin Cisplatin Cyclophosphamid... Etoposide Phosp... Isotretinoin Laboratory Biom... Peripheral Bloo... Thiotepa Vincristine Sul... Vorinostat | 2 Months - 47 Months | National Cancer Institute (NCI) | |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609840 | Hematologic Mal... Nonmalignant Di... Immune Deficien... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Thiotepa | - 17 Years | University of California, San Francisco | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
